!"#$%&'(!)*+,(#-./0!1"2-&

)&2!34,(5(657(!83!(9:!;

&(3<(= >%&?(@!A; 0 &B,"'86

&(3<(= C%!%6D'9A; #6%C<8=!!A(=%&

&(3<(= 18$('! 2EF<'86

2G!3'(!4%#C9&BH# I&<F=&J&KL3M13'(!CK'9(0($J6D'<N0! !%OO(#@<D*C(<0!5DAP%0

GA"#@<D*C(<0!; $J(=%Q,(6D,$J%?6

4.C. 2543

DRUG USE EVALUATION OF

CEFTRIAXONE

AT BUMRUNGRAD HOSPITAL

MISS JINDAPORN TAPANEEYAKUL

MISS SIRILUK LERTSUWANNAWIN

MISS OUMAKORN HOSAKUL

A SPECIAL PROJECT SUBMITTED IN PARTIAL FULLFILMENT

OF THE REQUIREMENT FOR

THE BACHELOR DEGREE OF SCIENCE IN

PHARMACY

FACULTY OF PHARMACY

MAHIDOL UNIVERSITY

2000

!"#$%&'

()*+,-./0)123%0+4567)'*84.1.8)9:%0 0; <0)=9)0>?)@

!"#$%&'( )*"+,-./0, 1!&!02.3'( 40!15/6&&'$6!", 7/8$.& 9:;5./0 '0A0)%@!BC()D/>0: *&+<$ 8"=.$")!./0*

, 4>0!81&+ %/88$?.@&* , .8012.#!A 4&B7?4 &!C&/;? **

*%$D6!<$4%52<.&&8 D'-4%52<1$5)&( 8E$6!=,$02,8E!#0 **FG$,4%52<.&&8 9&?H,$I$0IJ$&/?&$3K&( "<0E<0"#F: 4LMN)&7-9L", .$&*&-48!".$&O<P,$

.$&*&-48!".$&O<P,$4*Q"I=I$==+R5J$D2CS7?4%52<.&O".$&*&-,/.)(E02..$&I&!I$0=$?4%52<.&&8LTR?4*Q"U"6D!#OE8;4HBR74H!R8D/'%$H<+6!)S7?V@P*G6, 4LMN)&7-9L" 4*Q",$*W!<+6"-O".0/;84LMM-9&5*7&!"&/;"=+R 3 LTR?8+X=Y!AD&7ID0/84<BZ7.6P$?=2Z?4<BZ7U.&8I6. U.&80I )07# "4<BZ7N8;HTR?77.L!4 " =J$OEP8+.$&O<P,$4LMN)&7-9L"7,;$?UH&;E0$,

7,;$?N&.[)$8E$.8+.$&O<P,$7,;$?N8;4E8$-587$ 5;?V0OEP4.!#.$&5!Z"4*0B7?D;$O<P ;$,O".$&&2.3$ &68N*\T?.$&UH&;.&- $,S7?4<BZ7#BZ7,$ O"9&?H,$I$0N#P 62)\/*&-5?D(S7?.$&1T.3$"+Z 4HBR7*&-48!"D6$84E8$-58S7?.$&O<P,$4LMN)&7-9L"O"

9&?H,$I$0IJ$&/?&$3K&( 9#,*&-48!"UII,P7"E02?)2Z?U);4#B7" 483$," – HX3%$D8 2543 U0-=J$.$&*&-48!"4*&+,I4=+,I.2I4.'](8$)&^$"O".$&O<P,$4LMN)&7-9L"=+R.J$E"#N6P9#,8+ J$"6"V@P*G6, 56 &$, LTR?UI;?4*Q"V@P*G6,4#[. ( 0 – 12 *_ ) J$"6" 20 &$, D!#4*Q"&P7,0- 35.71 U0-V@P*G6,V@POEC; ( 12 *_STZ"N* ) J$"6"

36 &$, D!#4*Q"&P7,0- 64.29

V0.$&1T.3$HI6;$ 8+D6$8N8;4E8$-58O".$&O<P,$4LMN)&7-9L"=2Z?O"V@P*G6,4#[.U0-O"V@P*G6,V@POEC; 9#,O"V@P*G6,4#[.8+ J$"6" 18 &$, D!#4*Q"&P7,0- 90.00 U0-O"V@P*G6,V@POEC;8+ J$"6" 30 &$,

D!#4*Q"&P7,0- 83.33 LTR?D6$8N8;4E8$-58=+RHIDB7 .$&O<P,$4LMN)&7-9L"O"SP7I;?O<P=+RN8;N#P8+.J$E"#N6P U0-&-,-460$O".$&O<P,$"P7,.6;$=+R.J$E"#N6P U0-48BR7*&-48!"V0.$&&2.3$E02? $..$&O<P,$ 9#,H! $&'$ $. 7/'E%@8!, 48[#40B7#S$6 U0-.$&.J$ 2#4<BZ7UID=+4&+,HI6;$ V@P*G6,5;6"OEC;N8;8+NSPE02?.$&O<P,$ 5;6"48[#40B7#S$6U0-.$&.J$ 2#UID=+4&+,N8;5$8$&\"J$8$*&-48!"V0.$&&2.3$N#P4"BR7? $.N8;8+.$&52R?)&6 E02? $.O<P,$4LMN)&7-9L"

V0S7?.$&1T.3$<+ZOEP4E["6;$ U8PV@P*G6,5;6"OEC; -8+V0.$&&2.3$=+R#+E02?.$&O<P,$4LMN)&7-9L" U);48BR7H! $&'$D6$84E8$-58O".$&O<P4LMN)&7-9L"O"9&?H,$I$0IJ$&/?&$3K&(HI6;$5;6"E"TR?,2?4*Q".$&O<P,$7,;$?N8;584E)/58V0)$84.'](8$)&^$".$&O<P,$ U0-7$ =J$OEP4.!#.$&5!Z"4*0B7?D;$O<P ;$, &68N*\T?.$&4.!#V0.&-=IO".$&=J$OEP4<BZ7#BZ7,$4&[6STZ"#P6,

!

Abstract

Drug use evaluation of ceftriaxone at Bumrungrad hospital

Jindaporn tapaneeyakul, Siriluk lertsuwannawin, Oumakorn hosakul

Project advisor: Preecha Montakantikul*, Chalermsri Pummangura

*,

Kamolsak Ruengjaroenrung**

*Department of Pharmacy, Mahidol University

**Pharmacy Department, Bumrungrad Hospital

Keyword: Ceftriaxone, Drug use evaluation

Drug use evaluation (DUE) is an important role of

pharmacist in implementation of new concept of pharmaceutical

care. This would contribute to quality of life of patients. Ceftriaxone is a beta-lactam antibiotic in the group called third generation

cephalosporins which has broad spectrum activity. It is active against most gram-positive, gram-

negative aerobic and anaerobic bacteria. However, inappropriate use of the medication may

result in high expenditures in treatment course and spreading of resistant organisms.

The purpose of this study was to retrospectively evaluate the rational use of

ceftriaxone in Bumrungrad hospital during April-May 2000 by comparing with standard criteria for

ceftriaxone utilization. There were 56 cases with 20 cases (35.71%) of pediatric patients (0-12

years ) and 36 cases (64.29%) of adult and adolescent patients ( 12 years).

The results showed that the inappropriate drug use in pediatric patients was 18

cases (90.00%) and adult patients was 30 cases (83.33%). The majority of inappropriateness

were indication and duration of drug therapy. Outcome of therapy in terms of temperature, white

blood cell count (WBC) and bacterial eradication, showed that most patients became afebrile after

ceftriaxone therapy. WBC normalization and bacterial eradication could not be evaluated because

of no repeated test available.

In conclusion, the result of this study indicated that although most patients have

good outcome after ceftriaxone therapy, the use of ceftriaxone was not completely appropriate

which may result in high expenditures in treatment course and spreading of resistant organism.